2024年 業績

＜論文＞

1. Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
   Hirotsu Y, Nakagomi T, Nagakubo Y, Goto T, Omata M.
   Sci Rep. 2024;14(1):1594.
2. In Response to p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
   Sakamoto I, Kagami K, Nozaki T, Hirotsu Y, Amemiya K, Oyama T, Omata M.
   Am J Surg Pathol. 2024;48(3):374-375. 
3. Effectiveness of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 bivalent vaccine on symptoms in healthcare workers with BA.5 infection.
   Hirotsu Y, Takatori M, Mochizuki H, Omata M.
   Vaccine X. 2024;17:100433.
4. Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer.
   Nozaki T, Sakamoto I, Kagami K, Amemiya K, Hirotsu Y, Mochizuki H, Omata M.
   J Gynecol Oncol. 2024.　in press
5. Changes in Viral Dynamics Following the Legal Relaxation of COVID-19 Mitigation Measures in Japan From Children to Adults: A Single Center Study, 2020-2023.
   Hirotsu Y, Nagakubo Y, Maejima M, Shibusawa M, Hosaka K, Sueki H, Mochizuki H, Omata M.
   Influenza Other Respir Viruses. 2024;18(3):e13278.
6. Liquid biopsy of wash samples obtained via endoscopic ultrasound-guided fine-needle biopsy: Comparison with liquid biopsy of plasma in pancreatic cancer.
   Ohyama H, Hirotsu Y, Amemiya K, Amano H, Hirose S, Oyama T, Iimuro Y, Kojima Y, Mikata R, Mochizuki H, Kato N, Omata M.
   Diagn Cytopathol. 2024;52(6):325-331. 
7. The efficacy of bile liquid biopsy in the diagnosis and treatment of biliary tract cancer.
   Miura Y, Ohyama H, Mikata R, Hirotsu Y, Amemiya K, Mochizuki H, Ikeda J, Ohtsuka M, Kato N, Omata M.
   J Hepatobiliary Pancreat Sci. 2024. in press